Based on the most recent data from Jun 22, 2026, AZN's PEG ratio comes in at 0.78. This metric factors in a PE of 26.29 with an earnings growth rate of 33.9%. Relative to the 0.74 average from the previous four quarters, the PEG ratio has grown by 6%.
Looking at the last ten years, AZN's PEG ratio has has been around 1.15 on average. At 0.78, today's PE to growth ratio sits 32% below its historical average. Within the last ten years, the Jun 2024 quarter recorded the highest PEG value at 7.81. At 0.03, the Dec 2022 quarter showed the minimum PEG ratio in this period.
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.61 | 27.86 | 45.4% |
| 2024 | 1.59 | 28.86 | 18.2% |
| 2023 | 0.43 | 35.08 | 81.1% |
| 2022 | 0.03 | 63.96 | 2,550% |
| 2021 | N/A | 1,456.25 | -96.7% |
| 2020 | 0.3 | 40.98 | 136.9% |
| 2019 | N/A | 96.82 | -39.4% |
| 2018 | N/A | 44.68 | -28.3% |
| 2017 | N/A | 29.28 | -14.4% |
| 2016 | 0.82 | 19.73 | 24.2% |
| 2015 | 0.24 | 30.45 | 127.6% |
| 2014 | N/A | 71.82 | -52% |
| 2013 | N/A | 29.1 | -58.8% |
| 2012 | N/A | 9.55 | -32.1% |
| 2011 | 0.21 | 6.35 | 30.2% |
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 0.87 | 29.39 | 33.9% |
| Dec 2025 | 0.61 | 27.86 | 45.4% |
| Sep 2025 | 0.56 | 25.28 | 44.9% |
| Jun 2025 | 0.91 | 26.12 | 28.6% |
| Mar 2025 | 1.3 | 29.34 | 22.5% |
| Dec 2024 | 1.59 | 28.86 | 18.2% |
| Sep 2024 | 3.61 | 37.19 | 10.3% |
| Jun 2024 | 7.81 | 37.5 | 4.8% |
| Mar 2024 | 0.95 | 33.13 | 35% |
| Dec 2023 | 0.43 | 35.08 | 81.1% |
| Sep 2023 | 0.15 | 35.64 | 242.3% |
| Jun 2023 | 0.08 | 36.06 | 478.1% |
| Mar 2023 | 0.1 | 45.82 | 452.3% |
| Dec 2022 | 0.03 | 63.96 | 2,550% |
| Sep 2022 | N/A | 98.81 | -14% |
AZN's PEG ratio today is below the 3, 5 and 10-year averages.
Astrazeneca's PEG of 0.78 is above the Healthcare sector average but below the industry average. Compared to its Healthcare sector average of 0.55, Astrazeneca's PEG is 42% higher.
Compared to its peers, AZN has a PEG ratio under stock NVS, while above LLY's and BMY's.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| LLY ELI LILLY & Co | 0.3 | $1.04T |
| BMY Bristol Myers Squibb Co | 0.46 | $111.7B |
| AZN Astrazeneca plc | 0.78 | $273.29B |
| NVS Novartis AG | 2.31 | $284.17B |
| PFE Pfizer Inc | N/A | $142.94B |
| MRK Merck & Co Inc | N/A | $285.22B |
| JNJ Johnson & Johnson | N/A | $556.77B |
| BIIB Biogen Inc | N/A | $29.48B |
| ABT Abbott Laboratories | N/A | $152.98B |
AZN shows a PEG ratio of 0.78, per Jun 22, 2026 data.
AZN's 3-year PEG ratio average stands at 1.57.
AZN's 5-year PEG ratio average stands at 1.3.
The Jun 2024 quarter marked the ten years high at 7.81 for AZN's PEG ratio.
AZN currently has a PEG ratio 32% below its 10-year average.
Computing the PEG ratio involves dividing the PE ratio by the company's EPS growth (YoY TTM). As of Jun 22, 2026, Astrazeneca has a P/E ratio of 26.29. Earnings grew at 33.9% over the TTM period ending Mar 2026. Applying the formula, this produces a price to earnings growth ratio of 0.78. PEG RATIO(0.78) = PE RATIO(26.29) / EPS GROWTH(33.9%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.